Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Currently Reading
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019

Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs

Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.


Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.

Transcript

What is the typical lag time between a drugs approval and its availability in the electronic health records with the physicians being able to order it?

One of the challenges is when there is a new regimen that’s been approved, how long is it going to take to get into the EMR, remembering that the electronic medical records is the platform for choosing your regimens. We recently looked at this and presented as a poster at ISPOR this year where we looked at NCCN and approved regimens through the National Network of Cancer Centers and we found it was on average 15 days between approval by NCCN and being incorporated into our EMR. So, physicians on average only had to wait 2 weeks for them to be able to have this new regimen, and also some of this comes with new biomarker information so we’ve done the same. We’re incorporating new biomarkers that will direct you to new treatment in the same fashion with the same sort of turnaround time. 

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up